commonly requested. 26
However, testing is fallible; depending on the
marker, 5-50% of these tests may provide false
positive results. This can lead to further testing,
avoidable referrals, misdiagnosis, inappropriate
management, and even lawsuits. 27-35 Given that
up to 70% of medical decisions are based on
results of testing for diagnostic markers, 36-39
and that approximately 15% of medical cases in
developed countries are misdiagnosed, leading
to substantial costs, 40-44 it is vital that test results
are reliable.
When you get an EliA TM test result, you
can trust it to help you make the right
clinical decision – leading to better patient
outcomes
EliA TM rheumatic disease tests* have been shown
consistently to provide the most clinically
accurate results, when compared with alternative
tests, 45-57 meaning:
• The high sensitivity, even for difficult-to-detect
autoantibodies such as Ro, 58 ensures that you
detect a comparable number of patients
• The superior specificity of EliA rheumatic
disease tests* minimises the number of false
positives – potentially reducing avoidable
investigations and treatment
• You can correctly diagnose patients sooner,
ensuring they receive the best management
during the window of opportunity, and improving
outcomes
What are the benefits of using EliA TM tests?
Outstanding quality
• EliA best-in-class tests 45-57
• Results when you need them – Phadia TM
Laboratory Systems have outstanding
reliability 49
• Proven reproducibility – demonstrated
across >4,800 laboratory systems installed
worldwide 49
Cost savings
EliA tests support an early, accurate diagnosis,
which can help to minimise:
• Follow-up costs associated with misdiagnoses
• Avoidable treatments
• Avoidable emergency care
• Risk of malpractice lawsuits
EliA CTD
single
parameters
• EliA TM dsDNA well
• EliA TM SmDP-S well
• EliA TM U1RNP well
• EliA TM RNP70 well
• EliA TM Ro well
• EliA TM Ro60 well
• EliA TM Ro52 well
• EliA TM La well
• EliA TM Scl-70 s well
• EliA TM CENP well
• EliA TM Jo-1 well
• EliA Rib-P well
• EliA TM RNA Pol III well
• EliA TM PM-Scl well
• EliA TM PCNA well
• EliA TM Mi-2 well
• EliA TM Fibrillarin well
EliA rheumatic disease tests help bring clarity from uncertainty
The broad testing menu of EliA rheumatic disease tests can support, with a high degree of
certainty, 45-57 differential diagnosis of rheumatic disease
Rheumatoid arthritis
• EliA TM CCP well
• EliA TM RF IgM well
• EliA TM RF IgA well
• EliA TM RF IgG well
References
1 The General Practice Guide to
Autoimmune Diseases. P.L. SYaM,
editor: Pabst Science Publishers,
Lengerich Berlin; 2012
2 Irvine S, et al. Ann Rheum Dis
1999;58:510–13.
3 Gray M, Nuki J. Rheumatology
(Oxford) 2001;40(Suppl 1):60. 23
4 Jeyaratnam R, et al.
Rheumatology (Oxford)
2001;40(Suppl 1):29.
5 Potter T, et al. Rheumatology
(Oxford) 2002;41:953–5; author
reply 5.
6 Raza K, et al. Ann Rheum Dis
2011;70:1822–5
7 Rodriguez-Polanco E, et al.
Rheumatol Int 2011;31:657–65.
8 Nanji JA, et al. J Rheumatol
2012;39:707–11.
9 Sørensen J, Lund Hetland M.
Ann Rheum Dis. 2015; 74(3): e12.
10 Raciborski F, et al.
Rheumatologia. 2017; 55(4):
169–176.
11 Cavagna L, et al. Medicine
(Baltimore). 2016 95(39): e4827.
12 Sjögren’s Syndrome
Foundation, SSF Launches
5-Year Breakthrough Goal.
2012. Available at: http://www.
sjogrens.org/home/about-the-
foundation/breakthrough-goal-
[Last accessed April 2019].
13 Solans-Laqué R, et al. Semin
Arthritis Rheum 2011; 41:
415-423.
14 Gergianaki I, Bertsias G,
Frontiers Medicine 2018; 5:161
Connective tissue
diseases
• EliA TM CTD Screen well
• EliA TM Symphony S well
• EliA TM Single CTD
parameters ANCA-associated
vasculitis
• EliA TM PR3 S well
• EliA TM MPO S well
• EliA TM GBM well Antiphospholipid
syndrome
• EliA TM Cardiolipin IgG
well
• EliA TM β2-Glycoprotein
I well
15 Lupus UK, People with lupus
are waiting more than 6 years to
get a diagnosis in the UK, 2018.
Available at: //www.lupusuk.org.
uk/six-year-diagnosis-delay/.
[Last accessed July 2019.]
16 Oglesby A, et al, Appl Health
Econ Health Policy. 2014;12:179–
90. doi: 10.1007/s40258-014-
0085-x.
17. Malik A, et al. Frontiers in
Neurology 2016;7:64.
18 Rua-Figueroa Inigo; Arthritis
Care & research 2017;69(1):38-45.
19 Fallahi P, et al. Front.
Endocrinol. 8:266. doi: 10.3389/
fendo.2017.00266.14.
20 Caio G, et al. Gastroenterol
Hepatol Bed Bench
2018;11(3):244-249.
21 Barhamain AS, et al. Open
Access Rheumatol. 2017;9:
139-50.
22 Nell VPK, et al Ann Rheum Dis
2005;64 1731-1736
23 Romao VC, et al. RMD Open.
2018;4(Suppl 1):e000789.
24 Kuhn A, et al. Dtsch Arztebl Int.
2015;112(25):423-32.
25 Saketkoo et al. Am J Med
Sci. 2014; 347(1):doi:10.1097/
MAJ.0b013e3182a55d24.
26 Kavanaugh A, et al. Arch
Pathol Lab Med 2000;124:71–8.
27 Saber AS, et al. BMJ Qual Saf
2013;22:672-680.
28 Suarez-Almazor ME. J.
Rheumatology 1998;25(10):
1980-5.
29 Gamez-Nava JI, et al. British Journal of Rheumatology
1998;37:1215-1219.
30 Gran JT, et al. Clinical
Rheumatology 2000;19:(6) 450-4.
31 Gonzáles-Buitrago M. Clin
Chim Acta 2006;361 (1-2):50-7.
32 Abeles AM, et al. The American
Journal of Medicine 2013; 126:
342-348.
33 Fitch-Rogalsky C, et al. PLOS
2014;9 (4)1-8.
34 Rasmussen A, et al.
Rheumatology 2016.
35 American College of
Rheumatology, Position
Statement on Methodology
of Testing for Antinuclear
Antibodies. Available at: https://
www.rheumatology.org/
Portals/0/Files/Methodology%20
of%20Testing%20
Antinuclear%20Antibodies%20
Position%20Statement.pdf.x
[Last accessed July 2019.]
36 Badrick T, Clin Biochem Rev
2013;34: 43-6.
37 Kruse-Jarres JD, Lab. Med
1994;18:21
38 White paper diagnet, EDMA,
2010.
39 Ulrich-Peter R, et al. PLoS One
2016; 11(3): e0149856.
40 Leape L, et al. New England
Journal of Medicine 1991; 324:
377-384.
41 Singh H, et al. BMJ Qual Saf
2014;23:727–731.
42 Newman-Toker D, et al. JAMA
2003;01:10
43 The Telegraph, One in six NHS patients ‘misdiagnosed’.
2009. Available at: http://www.
telegraph.co.uk/news/health/
news/6216559/One-in-six-NHS-
patientsmisdiagnosed.html [Last
accessed July 2019.]
44 Washington Post,
Misdiagnosis is more
common than drug errors or
wrongsitesurgery. 2013. Available
at: https://www.washingtonpost.
com/national/health-science/
misdiagnosis-is-more-common-
than-drug-errors-or-wrong-
sitesurgery/2013/05/03/
5d71a374-9af4-11e2-a941-
a19bce7af755_story.html?utm_
term=.31a433743084. [Last
accessed July 2019.]
45 Mathsson Alm L, et al. Clin Exp
Rheumatol 2017; Nov 28 [Epub
ahead of print].
46 Nishimura K, et al. Ann Intern
Med 2007; 146:797-808.
47 Gonzalez C, et al. Clinica
Chimica Acta 2005; 359: 109-114.
editor: Pabst Science Publishers,
Lengerich Berlin; 2012.
48. Van der Pol P, et al. Clinica
Chimica Acta 2018; 4 76: 154-159.
49 ThermoFisher Scientific
Internal Study
50 Mascialino B, et al. Ann Rheum
Dis 2018;77:1173.
51 Korsholm T, et al. Scand J
Rheumatol 2014;43:89.
52 Robier C, et al. Clinical
Chemistry and Laboratory
Medicine 2016;54(8):1365-1370.
53 Alpini C, et al. EliA Journal
13
HHE 2019 | hospitalhealthcare.com
2010 (Special Edition 1):3.
54 Pereira LM, et al. EliA Journal
2010 (Special Edition 1):6-7.
55 Otten HG, et al. Clin Exp
Rheumatol 2017.
56 Jeong S, et al PLoS ONE
2017;12(3).
57 Willems P, et al. Clin Chem
Lab Med 2018; DOI: https://doi.
org/10.1515/cclm-2017-0905
[epub ahead of print].
58 Adebajo AO, et al. Collected
reports on the rheumatic
diseases. 2005. Available at:
https://www.arthritisresearchuk.
org/~/media/Files/Education/
Hands-On/IP03-Sep-2000.ashx
[Last accessed July 2019.]
*EliA rheumatic disease tests
include: EliA CTD Screen, EliA
Symphony S , EliA CTD Single
Parameters, EliA CCP, EliA RF
isotypes, EliA Cardiolipin, EliA
β2-Glycoprotein I, EliA PR3 S , EliA
MPO S , EliA GBM